SkinBioTherapeutics plc
FINPROM Findings
2“Investor presentation ... Now that the Open Offer has been closed, SkinBioTherapeutics will organising a presentation for shareholders, via the Investor Meet Company platform, in the week commencing 30 June 2025.”
Presentation deliberately scheduled AFTER offer close — demonstrates the correct pattern (inform post-raise, not during). Good compliance example for case-study contrast.
“WRAP Retail Offer”
Standard Article 43 exemption launch. Balanced disclosure with risk warning.
RNS Announcements
3FY Trading Update
the Company began incurring costs in preparation for the initial Superdrug launch; the cash at the period end reflects this expenditure. The above figures are subject to review by the Company's auditors before publication of the final FY25 results later in the year. Post year end, July was a strong month with significant orders and good trading across the board, especially for the BTS business. Operationally, the team is busy preparing for the launch of AxisBiotix™ in Superdrug stores in the Autumn and is on track. SkinBioTherapeutics records its revenues under regulatory accounting rule…
Result of WRAP Retail Offer
THIS ANNOUNCEMENT. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 WHICH FORMS PART OF THE LAWS OF ENGLAND AND WALES PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE WITHIN THE PUBLIC DOMAIN. SkinBioTherapeutics plc ("SkinBioTherapeutics" or the "Company") Result of WRAP Retail Offer 20 June 2025 - SkinBioTherapeutics plc (AIM:SBTX), a life science group focused on skin health, confirms, …
WRAP Retail Offer
THIS ANNOUNCEMENT. THE COMMUNICATION OF THIS ANNOUNCEMENT AND ANY OTHER DOCUMENTS OR MATERIALS RELATING TO THE WRAP RETAIL OFFER AS A FINANCIAL PROMOTION IS ONLY BEING MADE TO, AND MAY ONLY BE ACTED UPON BY, THOSE PERSONS IN THE UNITED KINGDOM FALLING WITHIN ARTICLE 43 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (WHICH INCLUDES AN EXISTING MEMBER OF SKINBIOTHERAPEUTICS PLC). ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO SUCH PERSONS AND WILL BE ENGAGED IN ONLY WITH SUCH PERSONS. THIS ANNOUNCEM…
Board of Directors
15| Name | Role | Appointed | Status |
|---|---|---|---|
| Rachel Lisa Parsonage | Interim Chief Executive Officer | 2026-03-09 | active |
| Martin Braddock Hunt | Executive Chairman | 2016-10-03 | active |
| Emily Bertram | Chief Financial Officer | 2025-05-31 | active |
| Alyson Margaret Levett | Non-Executive Director | 2026-01-01 | active |
| Dr Catherine Denise Prescott | Non-Executive Director | 2017-03-01 | active |
| Emily Lorraine Bertram | director, secretary | 2026-01-01 | active |
| Manprit Singh Randhawa | secretary | 2022-06-01 | active |
| Stuart Ashman | Executive Director | 2019-04-18 | active |
| Mark Kingsley Collingbourne | secretary | 2016-01-19 | active |
| Danielle Bekker | director | 2022-04-27 | active |
| Simon Jonathan Hewitson | director | 2025-04-28 | active |
| Robert James Taylor Laird | director | 2016-03-17 | active |
| Doug Quinn | secretary | 2016-12-22 | active |
| Dr Catherine Anne O'neill | director | 2016-03-17 | active |
| Stephen Patrick O'hara | director | 2015-06-10 | active |